Evonik News More News
Evonik Historical Prices
Date | Open | Close | Daily High | Daily Low |
---|
Price change over selected period:
0%
0
Evonik Analyst Opinions
- All
- Buy
- Hold
- Sell
Evonik Estimates* in EUR
2023 | 2024 | 2025 | 2026 | 2027 | |
---|---|---|---|---|---|
Revenue | 17,240 | 17,616 | 18,368 | 20,195 | 21,218 |
Dividend | 1.17 | 1.19 | 1.22 | 1.29 | 1.32 |
Dividend Yield (in %) | 5.99 % | 6.08 % | 6.23 % | 6.61 % | 6.76 % |
EPS | 1.70 | 2.00 | 2.27 | 2.86 | 3.28 |
P/E Ratio | 11.01 | 9.37 | 8.24 | 6.54 | 5.70 |
EBIT | 1,077 | 1,283 | 1,448 | 1,845 | 2,073 |
EBITDA | 2,223 | 2,440 | 2,633 | 3,022 | 3,372 |
Net Profit | 760 | 899 | 1,007 | 1,259 | 1,378 |
Net Profit Adjusted | 770 | 915 | 1,026 | 1,259 | 1,378 |
Pre-Tax Profit | 1,014 | 1,208 | 1,406 | 1,811 | 1,968 |
Net Profit (Adjusted) | 954 | 1,154 | 1,361 | 1,696 | - |
EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
EPS (GAAP) | 1.50 | 1.76 | 2.04 | 2.58 | 2.95 |
Gross Income | 4,309 | 4,586 | 4,779 | 5,437 | 5,805 |
Cash Flow from Investing | -714 | -881 | -859 | -1,329 | -1,406 |
Cash Flow from Operations | 1,922 | 1,980 | 2,086 | 2,130 | 2,346 |
Cash Flow from Financing | -596 | -699 | -727 | -485 | -480 |
Cash Flow per Share | 3.92 | 4.13 | 4.44 | - | - |
Free Cash Flow | 979 | 978 | 1,003 | 1,151 | 1,256 |
Free Cash Flow per Share | 2.07 | 2.04 | 1.86 | - | - |
Book Value per Share | 23.62 | 24.23 | 25.11 | - | - |
Net Debt | 3,151 | 2,891 | 2,892 | 3,378 | 3,699 |
Research & Development Exp. | 474 | 484 | 498 | - | - |
Capital Expenditure | 961 | 977 | 1,008 | 1,110 | 1,183 |
Selling, General & Admin. Exp. | 2,565 | 2,638 | 2,706 | - | - |
Shareholder’s Equity | 11,043 | 11,326 | 11,681 | 12,758 | 13,520 |
Total Assets | 22,219 | 22,431 | 22,396 | 23,765 | 24,682 |
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | 6 | 5 | 5 | 19 | 19 |
Average Estimate | 0.216 EUR | 0.217 EUR | 0.407 EUR | 1.698 EUR | 1.995 EUR |
Year Ago | 0.490 EUR | 0.760 EUR | 0.750 EUR | 2.260 EUR | 1.698 EUR |
Publish Date | 3/2/2023 | 5/9/2023 | 8/10/2023 | - | - |
Revenue Estimates | |||||
No. of Analysts | 4 | 3 | 3 | 18 | 17 |
Average Estimate | 4,459 EUR | 4,066 EUR | 4,404 EUR | 17,240 EUR | 17,616 EUR |
Year Ago | 4,091 EUR | 4,498 EUR | 4,772 EUR | 18,488 EUR | 17,240 EUR |
Publish Date | 3/2/2023 | 5/9/2023 | 8/10/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Evonik Dividend Calendar
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2022 | Evonik AG | - | - | EUR |
2021 | Evonik AG | 1.17 | 4.11 | EUR |
2020 | Evonik AG | 1.15 | 4.31 | EUR |
2019 | Evonik AG | 1.15 | 4.23 | EUR |
2018 | Evonik AG | 1.15 | 5.28 | EUR |
2017 | Evonik AG | 1.15 | 3.67 | EUR |
2016 | Evonik AG | 1.15 | 4.05 | EUR |
2015 | Evonik AG | 1.15 | 3.76 | EUR |
2014 | Evonik AG | 1.00 | 3.69 | EUR |
2013 | Evonik AG | 1.00 | 3.37 | EUR |
2012 | Evonik AG | - | - | EUR |
2012 | Evonik AG | 0.92 | - | EUR |
2011 | Evonik AG | 0.91 | - | EUR |
2011 | Evonik AG | - | - | EUR |
2010 | Evonik AG | - | - | EUR |
2010 | Evonik AG | 0.86 | - | EUR |
2009 | Evonik AG | - | - | EUR |
*Yield of the Respective Date
Evonik AG Calendar
Event | Estimate | Info | Date |
---|---|---|---|
Earnings Report | 0.217 EUR | Q1 2023 Earnings Release | 05/09/2023 |
Annual General Meeting | - | Annual General Meeting | 05/31/2023 |
Earnings Report | 0.407 EUR | Q2 2023 Earnings Release | 08/10/2023 |
Earnings Report | - | Q3 2023 Earnings Release | 11/07/2023 |
Earnings Report | - | Q4 2023 Earnings Release | 02/29/2024 |
Earnings Report | - | Q1 2024 Earnings Release | 05/07/2024 |
Earnings Report | - | Q2 2024 Earnings Release | 08/01/2024 |
Earnings Report | - | Q3 2024 Earnings Release | 11/05/2024 |
Evonik AG Past Events
Event | Actual EPS | Info | Date |
---|---|---|---|
Earnings Report | 0.540 EUR | Q4 2022 Earnings Release | 03/02/2023 |
Shareholders' Meeting | - | - | 05/25/2022 |
Evonik Profile
Evonik Industries AG operates as a holding company, which engages in the manufacture of specialty chemical products. It operates through the following segments: Nutrition and Care, Resource Efficiency, Performance Materials, Services, and Other Operations. The Nutrition and Care segment produces specialty chemicals, principally for use in consumer goods for daily needs, and in animal nutrition and healthcare products. The Resource Efficiency segment supplies materials and specialty additives for environment-friendly and energy-efficient system solutions for the automotive, paints, coatings, adhesives, construction industries, and other sectors. The Performance Materials segment manufacture polymer materials and intermediates, mainly for the rubber, plastics, and agriculture industries. The Services segment comprises site management, utilities, waste management, technical, process technology, engineering, and logistics services for the chemical segments and external customers. The Other Operation segment consists management holding company, strategic research, and hidden reserves and liabilities. The company was founded in 1919 and is headquartered in Essen, Germany.
Moody’s Daily Credit Risk Score
Evonik Shareholder
Owner | in % |
---|---|
RAG-Stiftung | 56.90 |
Freefloat | 43.07 |
Mondrian Investment Partners Ltd. | 3.03 |
American Funds Global Balanced Fund | 1.32 |
American Funds Capital World Growth & Income Fund | 1.07 |
Capital Income Builder | 1.03 |
Bridge Builder International Equity Fund | 0.96 |
DWS Concept SICAV - Kaldemorgen | 0.90 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Evonik Management
Name | Job |
---|---|
Christian Kullmann | Chairman-Management Board |
Bernd Tönjes | Chairman-Supervisory Board |
Ute Wolf | Chief Financial Officer |
Thomas Wessel | Chief HR Officer & Director-Labor Relations |
Andreas Fischer | Chief Innovation Officer |
Kai Kirchhoff | Director-Financial Planning & Reporting |
Anke Dassler | Head-Accounting |
Yann d'Herve | Head-Care Sol Business Line, Nutrition Care Div |
Tim Lange | Head-Investor Relations |
Maike Schuh | Head-Performance Materials Division |
Angela Titzrath | Independent Member-Supervisory Board |
Barbara Ruth Albert | Independent Member-Supervisory Board |
Ulrich Weber | Independent Member-Supervisory Board |
Volker Trautz | Independent Member-Supervisory Board |
Barbara Grunewald | Independent Member-Supervisory Board |
Aldo Belloni | Independent Member-Supervisory Board |
Harald Sirkorski | Member-Supervisory Board |
Gerd Schlengermann | Member-Supervisory Board |
Michael Rüdiger | Member-Supervisory Board |
Cedrik Neike | Member-Supervisory Board |
Werner Fuhrmann | Member-Supervisory Board |
Thomas Sauer | Member-Supervisory Board |
Hussin El Moussaoui | Member-Supervisory Board |
Martin Kubessa | Member-Supervisory Board |
Alexandra Krieger | Member-Supervisory Board |
Gerhard Ribbeheger | Member-Supervisory Board |
Martina Reisch | Member-Supervisory Board |
Martin Albers | Member-Supervisory Board |
Harald Schwager | Vice Chairman-Management Board |
Karin Erhard | Vice Chairman-Supervisory Board |